Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 7:12:6605-6616.
doi: 10.2147/IJN.S143938. eCollection 2017.

Delivery of paeonol by nanoparticles enhances its in vitro and in vivo antitumor effects

Affiliations

Delivery of paeonol by nanoparticles enhances its in vitro and in vivo antitumor effects

Cong Chen et al. Int J Nanomedicine. .

Abstract

Paeonol (Pae; 2'-hydroxy-4'-methoxyacetophenone) has attracted intense attention as a potential therapeutic agent against various cancers. However, the use of Pae is limited owing to its hydrophobicity. Recently, biodegradable polymeric nanoparticles with amphiphilic copolymers have been used as drug carriers; these have better bioavailability and are promising tumor-targeted drug delivery systems. In the current study, we prepared Pae-loaded nanoparticles (Pae-NPs) with amphiphilic block copolymers using nanoprecipitation. The physiochemical characteristics and antitumor effects of nanoparticles were evaluated in different cancer cells. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays showed substantial inhibition of cell growth by Pae-NPs. Moreover, lower doses of Pae-NPs inhibited cell growth more efficiently than the equivalent doses of free Pae. Inhibition was characterized by significant elevation of intracellular reactive oxygen species and subsequent inhibition of Akt and regulation of apoptotic proteins, which could be partly reversed by pretreatment with the antioxidant N-acetylcysteine. In vivo results also demonstrated that Pae-NPs could exert much stronger antitumor effects than free Pae. Therefore, Pae-NPs represent a promising delivery system to overcome the low solubility of Pae and enable its use in treating cancer.

Keywords: drug delivery; nanoparticles; paeonol.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Characterization of Pae-NPs. Notes: (A) Size distribution of Pae-NPs measured by DLS. (B) Size changes of Pae-NPs at room temperature. (C) Cumulative release profile of Pae-NPs. Abbreviations: Pae-NPs, Pae-loaded nanoparticles; DLS, dynamic light scattering.
Figure 2
Figure 2
Dose-dependent cytotoxicity of Pae and Pae-NPs against (A) A549 and (B) NCI-H1975 cells. Notes: Data are presented as mean ± SD (n=3). *p<0.05, **p<0.01, compared to the control group. Abbreviations: Pae, paeonol; Pae-NPs, Pae-loaded nanoparticles; E-NPs, empty nanoparticles; SD, standard deviation.
Figure 3
Figure 3
Cellular uptake of coumarin-6-loaded fluorescent Pae-NPs by cancer cells. Notes: (A, B) Representative microscopic images of A549 cells incubated with coumarin-6-loaded Pae-NPs for 2 hours; (A) bright fields with higher magnification; (B) fluorescent fields with higher magnification. (C) Cellular uptake efficiency of Pae-NPs by A549 and NCI-H1975 cells. Data are presented as mean ± SD (n=3). **p<0.01, compared to the control group. Abbreviations: Pae-NPs, Pae-loaded nanoparticles; SD, standard deviation.
Figure 4
Figure 4
Effects of Pae and Pae-NPs on apoptosis in A549 cells without (A) or with (B) the presence of NAC. Abbreviations: Pae, paeonol; Pae-NPs, Pae-loaded nanoparticles; E-NPs, empty nanoparticles; NAC, N-acetylcysteine; Con, control; FITC, fluorescein isothiocyanate; PI, propidium iodide.
Figure 5
Figure 5
Detection of intracellular ROS. Notes: (A) DHE fluorescence images of A549 cells treated with different agents (control; E-NPs; Pae [50 μg/mL]; Pae-NPs [at an equivalent dose of 50 μg/mL]). (B) Intracellular DHE fluorescence intensity. Data are represented as mean ± SD. *p<0.05, compared to the control group; #p<0.05, compared to the Pae group or Pae-NPs group. Abbreviations: Pae, paeonol; Pae-NPs, Pae-loaded nanoparticles; E-NPs, empty nanoparticles; SD, standard deviation; DHE, dihydroethidium; ROS, reactive oxygen species; NAC, N-acetylcysteine; Con, control.
Figure 6
Figure 6
Effects of free Pae or Pae-NPs on the expression of Akt pathway proteins in A549 cells. Notes: (A) Blots of p-Akt and Akt from cells treated with different agents. (B) Semi-quantification of protein expression. Data are represented as mean ± SD. Abbreviations: Pae, paeonol; Pae-NPs, Pae-loaded nanoparticles; E-NPs, empty nanoparticles; SD, standard deviation; NAC, N-acetylcysteine; Con, control.
Figure 7
Figure 7
Effect of free Pae or Pae-NPs on the expression of apoptotic proteins in A549 cells. Notes: (A) Blots of Bcl-XL, Bax, and Bcl-2 from cells treated with different agents. (B) Semi-quantification of protein expression. Data are represented as mean ± SD. Abbreviations: Pae, paeonol; Pae-NPs, Pae-loaded nanoparticles; E-NPs, empty nanoparticles; SD, standard deviation; NAC, N-acetylcysteine; Con, control.
Figure 8
Figure 8
Effect of free Pae or Pae-NPs on the expression of caspase-3 and cleaved caspase-3 proteins in A549 cells. Notes: (A) Blots of caspase-3 and pro-caspase-3 from cells treated with different agents. (B) Semi-quantification of protein expression. Data are represented as mean ± SD. Abbreviations: Pae, paeonol; Pae-NPs, Pae-loaded nanoparticles; E-NPs, empty nanoparticles; SD, standard deviation; NAC, N-acetylcysteine; Con, control.
Figure 9
Figure 9
In vivo antitumor efficacy of Pae-NPs. Notes: The mice were intravenously administered with PBS, E-NPs, free Pae, or Pae-NPs every 2 days for three consecutive injections. (A) Growth inhibition study in the A549 xenograft model. (B) Body weight changes for the tumor bearing mice after various formulations were given to mice on the indicated days. Data are represented as mean ± SD (n=6). *p<0.05, **p<0.01, compared to the control group; #p<0.05, compared to the Pae group. Abbreviations: Pae, paeonol; Pae-NPs, Pae-loaded nanoparticles; E-NPs, empty nanoparticles; SD, standard deviation; PBS, phosphate-buffered saline; Con, control.

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
    1. Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257. - PMC - PubMed
    1. Li X, Li R, Qian X, et al. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm. 2008;70(3):726–734. - PubMed
    1. Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release. 2007;118(1):7–17. - PubMed
    1. Sun GP, Wan X, Xu SP, Wang H, Liu SH, Wang ZG. Antiproliferation and apoptosis induction of paeonol in human esophageal cancer cell lines. Dis Esophagus. 2008;21(8):723–729. - PubMed

MeSH terms

LinkOut - more resources